Last Updated: November 13, 2026

Curium Company Profile

« Back to Dashboard


What is the competitive landscape for CURIUM

CURIUM has twenty-two approved drugs.

There are four US patents protecting CURIUM drugs.

Summary for Curium
US Patents:4
Tradenames:19
Ingredients:19
NDAs:22
Patent Litigation for Curium: See patent lawsuits for Curium

Drugs and US Patents for Curium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Curium IOFLUPANE I-123 ioflupane i-123 SOLUTION;INTRAVENOUS 213792-001 Mar 30, 2022 AP RX No No ⤷  Start Trial ⤷  Start Trial
Curium BEXLUTRY lutetium lu-177 dotatate SOLUTION;INTRAVENOUS 218525-001 Sep 14, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Curium PHOSPHOCOL P32 chromic phosphate p-32 INJECTABLE;INJECTION 017084-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial
Curium SODIUM CHROMATE CR 51 sodium chromate cr-51 INJECTABLE;INJECTION 016708-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Curium ULTRA-TECHNEKOW V4 technetium tc-99m sodium pertechnetate generator SOLUTION;INTRAVENOUS 017243-003 Feb 18, 2014 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Curium INDIUM IN 111 CHLORIDE indium in-111 chloride INJECTABLE;INJECTION 019841-001 Sep 27, 1994 DISCN Yes No ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Curium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Curium TECHNESCAN MAG3 technetium tc-99m mertiatide kit INJECTABLE;INJECTION 019882-001 Jun 15, 1990 5,573,748 ⤷  Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 5,384,113 ⤷  Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 6,123,916 ⤷  Start Trial
Curium TECHNESCAN HDP technetium tc-99m oxidronate kit INJECTABLE;INJECTION 018321-001 Approved Prior to Jan 1, 1982 4,497,744 ⤷  Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 5,776,894 ⤷  Start Trial
Curium ULTRATAG technetium tc-99m red blood cell kit INJECTABLE;INJECTION 019981-001 Jun 10, 1991 4,755,375 ⤷  Start Trial
Curium OCTREOSCAN indium in-111 pentetreotide kit INJECTABLE;INJECTION 020314-001 Jun 2, 1994 5,753,627 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Curium Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3347352 SPC/GB22/064 United Kingdom ⤷  Start Trial PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REGISTERED: UK EU/1/22/1671(FOR NI) 20220819; UK MORE ON HISTORY TAB 20220819
1178838 300736 Netherlands ⤷  Start Trial PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
2380576 20C1048 France ⤷  Start Trial PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729
2822954 2018/031 Ireland ⤷  Start Trial PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTRATION NO/DATE: EU/1/18/1289 20180625
2666774 CA 2020 00037 Denmark ⤷  Start Trial PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
1948158 93075 Luxembourg ⤷  Start Trial PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
2203431 2015/009 Ireland ⤷  Start Trial PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.